Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock Holdings Lifted by Fmr LLC

Fmr LLC raised its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 1,532.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 37,752 shares of the specialty pharmaceutical company’s stock after buying an additional 35,439 shares during the period. Fmr LLC owned approximately 0.12% of Collegium Pharmaceutical worth $1,459,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Foundry Partners LLC acquired a new stake in Collegium Pharmaceutical during the 2nd quarter valued at $492,000. Penserra Capital Management LLC purchased a new position in shares of Collegium Pharmaceutical during the 3rd quarter valued at $757,000. Squarepoint Ops LLC grew its holdings in shares of Collegium Pharmaceutical by 194.5% during the 2nd quarter. Squarepoint Ops LLC now owns 110,338 shares of the specialty pharmaceutical company’s stock valued at $3,553,000 after acquiring an additional 72,874 shares in the last quarter. BOKF NA purchased a new position in shares of Collegium Pharmaceutical during the 2nd quarter valued at $490,000. Finally, Renaissance Technologies LLC grew its holdings in shares of Collegium Pharmaceutical by 8.0% during the 2nd quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock valued at $49,314,000 after acquiring an additional 113,300 shares in the last quarter.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $30.09 on Monday. Collegium Pharmaceutical, Inc. has a 12-month low of $28.75 and a 12-month high of $42.29. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The firm has a market capitalization of $970.40 million, a PE ratio of 12.97 and a beta of 0.80. The firm has a 50-day moving average price of $33.24 and a 200 day moving average price of $34.38.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. HC Wainwright boosted their price target on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, September 5th. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Finally, Piper Sandler restated a “neutral” rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $42.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.